The double negative regulation of FAT10 and p53 plays a key role in the control of tumorigenesis, and the low level of UBA6 makes the tumor more immunogenic and increases the drug sensitivity of the tumor, which makes UBA6 a potential target for treating diseases (23, 24). Here, UBA6 is linked to neoplasm.